166 related articles for article (PubMed ID: 3516395)
1. Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study.
Vogler WR; Preisler HD; Winton EF; Gottlieb AJ; Goldberg J; Brennan J; Grunwald H; Rai K; Browman G; Miller KB
Cancer Treat Rep; 1986 Apr; 70(4):455-9. PubMed ID: 3516395
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of acute myeloid leukemia with amsacrine and high-dose cytosine arabinoside: a phase II trial].
Marit G; David B; Reiffers J; Broustet A
Bull Cancer; 1985; 72(1):37-41. PubMed ID: 3857082
[TBL] [Abstract][Full Text] [Related]
3. Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group.
Winton EF; Hearn EB; Martelo O; Presant CA; Adler S; Vogler WR; Raney M; Logan T; Silberman HM; Omura GA
Cancer Treat Rep; 1985; 69(7-8):807-11. PubMed ID: 2410119
[TBL] [Abstract][Full Text] [Related]
4. Amsacrine in refractory adult acute leukemia: a pilot study of the Southeastern Cancer Study Group.
Winton EF; Hearn EB; Vogler WR; Johnson L; Logan T; Raney M
Cancer Treat Rep; 1983 Nov; 67(11):977-80. PubMed ID: 6580070
[TBL] [Abstract][Full Text] [Related]
5. Treatment of acute leukemia with amsacrine and high-dose cytarabine.
Arlin ZA; Gaddipati J; Ahmed T; Mittelman A; Friedland M; Rieber E
Cancer Treat Rep; 1985 Sep; 69(9):1001-2. PubMed ID: 3839713
[TBL] [Abstract][Full Text] [Related]
6. Amsacrine in refractory acute leukemia.
Griffin JD; Maguire ME; Mayer RJ
Cancer Treat Rep; 1985; 69(7-8):787-9. PubMed ID: 3860296
[TBL] [Abstract][Full Text] [Related]
7. [Clinical activity of m-Amsa and the combination of m-Amsa with cytosine arabinoside].
Weil M; Auclerc MF; Schaison G; Auclerc G; Daubrisson A; Degos L; Caro J; Marty M; Jacquillat GI
Nouv Presse Med; 1982 Oct; 11(39):2911-4. PubMed ID: 6755389
[TBL] [Abstract][Full Text] [Related]
8. [Early phase II study of Idarubicin combined with cytarabine in acute myelogenous leukemia. Idarubicin Study Group].
Ogawa M; Masaoka T; Yamada K; Kimura K
Gan To Kagaku Ryoho; 1993 May; 20(7):907-14. PubMed ID: 8489297
[TBL] [Abstract][Full Text] [Related]
9. Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.
Estey EH; Kantarjian H; Keating M
Semin Oncol; 1993 Dec; 20(6 Suppl 8):1-5. PubMed ID: 8290966
[TBL] [Abstract][Full Text] [Related]
10. Phase I-II study of aclarubicin for treatment of acute myeloid leukemia.
Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Ribaud P; Schwarzenberg L
Cancer Treat Rep; 1984 Jun; 68(6):881-6. PubMed ID: 6587933
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of amsacrine and high-dose cytarabine for resistant acute myelogenous leukemia.
Decker RW; Ho WG; Champlin RE
Cancer Treat Rep; 1987 Sep; 71(9):881-2. PubMed ID: 3476204
[No Abstract] [Full Text] [Related]
12. AMSA--a promising new agent in refractory acute leukemia.
Lawrence HJ; Ries CA; Reynolds RD; Lewis JP; Koretz MM; Torti FM
Cancer Treat Rep; 1982 Jul; 66(7):1475-8. PubMed ID: 7046928
[TBL] [Abstract][Full Text] [Related]
13. Acridinyl anisidide (m-AMSA) therapy in 11 patients with refractory acute leukemia.
Naparstek E; Shinar E; Polliack A
Isr J Med Sci; 1984 Feb; 20(2):118-22. PubMed ID: 6546740
[TBL] [Abstract][Full Text] [Related]
14. A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia.
Arlin ZA; Ahmed T; Mittelman A; Feldman E; Mehta R; Weinstein P; Rieber E; Sullivan P; Baskind P
J Clin Oncol; 1987 Mar; 5(3):371-5. PubMed ID: 3546613
[TBL] [Abstract][Full Text] [Related]
15. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.
Archimbaud E; Fiere D; Treille-Ritouet D; Adeleine P; Guyotat D; Sebban C; Vuvan H; Viala JJ
Cancer Treat Rep; 1987 Jun; 71(6):571-4. PubMed ID: 3555788
[TBL] [Abstract][Full Text] [Related]
16. Treatment of acute nonlymphocytic leukemia with neocarzinostatin.
Griffin TW; Lister TA; Rybak ME; Rosenthal DS; Canellos GP; Woodruff R; Oliver KT
Cancer Treat Rep; 1979; 63(11-12):1853-6. PubMed ID: 160835
[TBL] [Abstract][Full Text] [Related]
17. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
[TBL] [Abstract][Full Text] [Related]
19. m-AMSA: phase II trial in advanced lymphoma and leukemia.
Case DC
Am J Clin Oncol; 1984 Aug; 7(4):357-60. PubMed ID: 6588746
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic trials of aclarubicin in previously treated acute leukemias and hematosarcomas].
Machover D; Goldschmidt E; Benavides M; Gastiaburu J; Vandenbulcke JM; Delgado M; Misset JL; Mathe G
Pathol Biol (Paris); 1987 Jan; 35(1):79-86. PubMed ID: 3550616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
